中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
Chinese Journal of Clinicians (Electronic Edition)
2015年
17期
3193-3196
,共4页
肺疾病,慢性阻塞性%布地奈德%急性加重期%雾化吸入
肺疾病,慢性阻塞性%佈地奈德%急性加重期%霧化吸入
폐질병,만성조새성%포지내덕%급성가중기%무화흡입
Pulmonary disease,chronic obstructive%Budesonide%Acute exacerbation%Atomization inhalation
目的：比较慢性阻塞性肺疾病急性加重期（AECOPD）吸入布地奈德与静脉滴注甲强龙的临床疗效及卫生经济学。方法回顾性分析山西医科大学第一医院住院的AECOPD患者121例，根据糖皮质激素应用情况分为：布地奈德低剂量组（3 mg/d，A组）33例，布地奈德高剂量组（6 mg/d， B组）32例，甲强龙组（40 mg/d，C组）28例，对照组（未用糖皮质激素，D组）28例，观察各组有效率、血气指标、不良反应、住院天数及费用并进行统计学分析。结果与D组比较，A、B、C组临床总有效率增高，差异均有统计学意义（均P＜0.05），各治疗组间比较差异均无统计学意义（均P＞0.05）。治疗后血气指标比较，与D组比较，A、B、C组动脉血氧分压（PaO2）升高，动脉血二氧化碳分压（PCO2）降低；与A组比较，B、C组PaO2升高，PCO2降低，差异均有统计学意义（均P＜0.05）；B组与C组比较差异均无统计学意义（均P＞0.05）。与C组比较，A、B、D组不良反应降低，差异均有统计学意义（均P＜0.05）。与D组比较，A、B、C组的住院天数、费用均减少；与A组比较， B、C组的住院天数、费用均减少，差异均有统计学意义（均P＜0.05）；B与C组比较差异无统计学意义（P＞0.05）。结论AECOPD吸入布地奈德6 mg/d疗效可靠，糖皮质激素的不良反应发生率低，患者的经济负担轻。
目的：比較慢性阻塞性肺疾病急性加重期（AECOPD）吸入佈地奈德與靜脈滴註甲彊龍的臨床療效及衛生經濟學。方法迴顧性分析山西醫科大學第一醫院住院的AECOPD患者121例，根據糖皮質激素應用情況分為：佈地奈德低劑量組（3 mg/d，A組）33例，佈地奈德高劑量組（6 mg/d， B組）32例，甲彊龍組（40 mg/d，C組）28例，對照組（未用糖皮質激素，D組）28例，觀察各組有效率、血氣指標、不良反應、住院天數及費用併進行統計學分析。結果與D組比較，A、B、C組臨床總有效率增高，差異均有統計學意義（均P＜0.05），各治療組間比較差異均無統計學意義（均P＞0.05）。治療後血氣指標比較，與D組比較，A、B、C組動脈血氧分壓（PaO2）升高，動脈血二氧化碳分壓（PCO2）降低；與A組比較，B、C組PaO2升高，PCO2降低，差異均有統計學意義（均P＜0.05）；B組與C組比較差異均無統計學意義（均P＞0.05）。與C組比較，A、B、D組不良反應降低，差異均有統計學意義（均P＜0.05）。與D組比較，A、B、C組的住院天數、費用均減少；與A組比較， B、C組的住院天數、費用均減少，差異均有統計學意義（均P＜0.05）；B與C組比較差異無統計學意義（P＞0.05）。結論AECOPD吸入佈地奈德6 mg/d療效可靠，糖皮質激素的不良反應髮生率低，患者的經濟負擔輕。
목적：비교만성조새성폐질병급성가중기（AECOPD）흡입포지내덕여정맥적주갑강룡적림상료효급위생경제학。방법회고성분석산서의과대학제일의원주원적AECOPD환자121례，근거당피질격소응용정황분위：포지내덕저제량조（3 mg/d，A조）33례，포지내덕고제량조（6 mg/d， B조）32례，갑강룡조（40 mg/d，C조）28례，대조조（미용당피질격소，D조）28례，관찰각조유효솔、혈기지표、불량반응、주원천수급비용병진행통계학분석。결과여D조비교，A、B、C조림상총유효솔증고，차이균유통계학의의（균P＜0.05），각치료조간비교차이균무통계학의의（균P＞0.05）。치료후혈기지표비교，여D조비교，A、B、C조동맥혈양분압（PaO2）승고，동맥혈이양화탄분압（PCO2）강저；여A조비교，B、C조PaO2승고，PCO2강저，차이균유통계학의의（균P＜0.05）；B조여C조비교차이균무통계학의의（균P＞0.05）。여C조비교，A、B、D조불량반응강저，차이균유통계학의의（균P＜0.05）。여D조비교，A、B、C조적주원천수、비용균감소；여A조비교， B、C조적주원천수、비용균감소，차이균유통계학의의（균P＜0.05）；B여C조비교차이무통계학의의（P＞0.05）。결론AECOPD흡입포지내덕6 mg/d료효가고，당피질격소적불량반응발생솔저，환자적경제부담경。
ObjectiveTo compare the curative effect and the health economics of budesonide inhalation and methylprednisolone intravenous in treating acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods121 patients with AECOPD hospitalized patients of the first hospital of Shanxi Medical University were enrolled in this study, according to the application of glucocorticoid hormone, the patients were divided into A group treated with low dose (3 mg/d) budesonide (33 cases), B group treated with high dose (6 mg/d) budesonide (32 cases), C group treated with methylprednisolone(40 mg/d, 28 cases) and D group not treated with any glucocorticoids (28 cases). In the four groups, the patients' clinical efficiency, blood gas analysis, adverse reactions, days in hospital and the hospitalization expenses were observed and statistically analyzed.ResultsA, B, C groups of the total clinical efficiency were higher than D group, and the differences were statistically significant (P<0.05). There was no statistical significance(P>0.05) among A, B, C groups. After the treatment of blood gas index, compared with D group, A, B, C groups’ PaO2 increased and PCO2 decreased, all the difference was statistically significant (P<0.05). Compared with A group, B, C groups’PaO2 increased and PCO2 decreased, all the difference was statistically significant (P<0.05). There was no statistical significance (P>0.05) between the B, C groups. The adverse reactions of A, B, D groups were lower than C group, and the difference was statistically significant (P<0.05). A, B, C groups of days in hospital, and hospitalization expenses were lower than D group, and the differences were statistically significant (P<0.05). Compared with A group, days in hospital, hospitalization expenses of B, C groups reduced, and all the difference was statistically significant (P<0.05). There was no statistical significance (P>0.05) between B, C groups. ConclusionThe inhaled budesonide 6 mg/d therapy is effective, and it reduces the side effects, and the economic burden.
